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Paragangliomas are neoplasms that arise from extra-adrenal chromaffin cells. Pancreatic paragangliomas are rare,
and few are malignant. To the best of our knowledge, no cases of functional pancreatic paragangliomas have been
reported in the literature to date. We present two cases of pancreatic paragangliomas with pathological confirmation.
In the case 1, clinical testing and pathological analysis revealed functional and malignant characteristics of the tumor,
which carried a poor prognosis. In case 2, functional paraganglioma was suspected. The clinical presentations and
outcomes of these two patients are summarized, and the relevant literature is reviewed. Because of the small number
of cases reported previously, few characteristics of these tumors are known. The best methods of predicting the
malignant and functional potential of these tumors remain unknown. We propose careful preoperative treatment and
close postoperative follow-up of paraganglioma patients because of the functional and malignant potential of these
tumors.
Keywords: Pancreatic neuroendocrine tumor, ParagangliomaBackground
Paragangliomas (PGLs) are rare neuroendocrine tumors
(NETs) that arise from extra-adrenal chromaffin cells of
the autonomic nervous system, with an average annual
incidence rate of only 2 to 8 per 1 million adults [1].
Pancreatic PGLs are uncommon. Only 20 cases have
been reported worldwide, and they have been limited to
individual case reports in either radiography or path-
ology journals [2,3]. The case reports published to date
contain no descriptions of functional pancreatic PGLs,
and few cases were malignant [4]. We present two cases
of pancreatic PGL. In one case, the clinical manifestation
revealed a functional pancreatic PGL with liver metasta-
ses. In the other, functional pancreatic PGL was sus-
pected. The clinical presentation and outcomes of the
two cases are summarized, and we describe the func-
tional and malignant potential of pancreatic PGLs based
on our review of the literature.* Correspondence: zhao8028@263.net
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Case 1
A 50-year-old woman presented to our institution with a
3-year history of intermittent hypertension, headache,
sweating and palpitation. Abdominal computed tomog-
raphy (CT) showed a 6-cm, solid, well-vascularized tumor
on the head of the pancreas, with multiple liver metasta-
ses. Fine-needle aspiration (FNA) was performed. The
cytopathological result indicated pancreatic PGL with typ-
ical double-positive chromogranin A(CgA) and synapto-
physin (Syn) staining. The patient underwent laparotomy
without special preoperative preparation. During the oper-
ation, the patient’s systolic blood pressure increased to
220 mmHg. Therefore, the operation was halted. Postop-
erative laboratory tests revealed the patient had a sixfold
increase in 24-hour urinary norepinephrine excretion,
consistent with functional pancreatic PGL. Chemotherapy
with 5-fluorouracil, mitomycin and doxorubicin was ad-
ministered postoperatively without significant remission.
The patient died 4 years after her initial diagnosis.Case 2
A 63-year-old man with a 10-year history of hyperten-
sion was admitted to the hospital for treatment of a sus-
pected functional pancreatic PGL, although symptomsLtd. This is an Open Access article distributed under the terms of the Creative
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tion, were not present. Abdominal CT revealed a 4-cm,
solid, well-vascularized tumor on the head of the pan-
creas and adjacent to the superior mesentery vein. 123I-
metaiodobenzylguanidine (123I-MIBG) imaging revealed
abnormal uptake in the region of the pancreatic head.
Although the patient had a normal level of 24-hour urin-
ary norepinephrine excretion, primary functional pan-
creatic PGL was suspected due to his hypertension
history. As a result, α-adrenergic receptor blockers were
administered for 2 weeks prior to surgery. During sur-
gery, the patient’s blood pressure remained stable, and
the tumor was resected successfully. Pathological ana-
lysis confirmed the diagnosis of pancreatic PGL, and the
tumor was positive for CgA and Syn, observed by per-
forming immunohistochemical analysis. The patient re-
ceived no subsequent adjuvant treatment, and his blood
pressure was normal 3 months after surgery.
Discussion
Primary pancreatic PGL is rare, with only 20 cases re-
ported in the literature to date. Similar to other pancre-
atic NETs, they are more likely to affect women than
men older than 40 years of age. Patients typically present
with abdominal pain or are asymptomatic, and PGL is
discovered incidentally on routine radiographic images.
Pancreatic PGLs can arise in any part of the pancreas,
although the majority of these tumors are located at the
head of the pancreas [4]. The size of the tumors ranges
from 3 to 20 cm. Larger tumors are often accompanied
by cystic changes. The location of pancreatic PGLs can
usually be identified by using abdominal CT or MRI,
which have high sensitivity for PGL. Functional 123I-
MIBG scans often provide accurate information on the
disease extent and biology [5], especially in malignant
cases, because of high uptake in chromaffin cells. PGL
cases are typically hypervascular, with cystic changes
mimicking most pancreatic NETs. Therefore, definitive
diagnosis requires pathological confirmation. FNA can
be performed preoperatively, but diagnostic accuracy is
low [4]. Immunohistochemical analysis is necessary to
confirm the presence of the characteristic CgA-Syn
double-positive cell populations [4].
PGLs rarely produce excess catecholamines [6], al-
though patients with functional PGL may have symp-
toms of catecholamine excess, such as hypertension,
headache and palpitation. Ultimately, the diagnosis of
functional pancreatic PGL is made on the basis of the
levels of catecholamines and their metabolites in plasma
or urine. To the best of our knowledge, no functional
pancreatic PGLs have been reported previously. Herein,
we present a patient with typical PGL symptoms and a
sixfold increase in 24-hour urinary norepinephrine ex-
cretion, consistent with the findings of a functional PGL.Because the patient’s norepinephrine levels were not
known preoperatively, the surgery was performed with-
out preoperative α-adrenergic receptor blockade treat-
ment, which resulted in unstable blood pressure that
necessitated halting the surgery. In the second case, as
the patient was suspected with functional pancreatic
PGL, he received α-adrenergic receptor blocker treat-
ment 2 weeks prior to the operation in order to avoid
the excess release of catecholamine.
PGLs are more likely to be malignant (29% 40%) [6].
Malignant PGLs are defined as those that metastasize,
recur or show evidence of local invasion [7]. Because of
the poor prognosis of malignant PGL, it is important to
distinguish between benign and malignant tumors before
surgery. Frequently, PGLs may develop metastases years
after the initial diagnosis [8], making early identification
of metastasis critical to improving outcomes. Unfortu-
nately, no reliable genetic, molecular or imaging markers
currently exist to predict the malignant potential of PGLs.
A multimodal approach in the treatment of patients
with PGL is mandatory, including advanced surgery, nu-
clear medicine, chemotherapy, radiotherapy and novel
biologically targeted drugs. Traditionally, treatment for
all PGLs has begun with complete surgical excision. In
addition, minimally invasive surgical techniques and
close cooperation with the anesthetist are critical to
minimizing intraoperative fluctuation of blood pressure.
Treatment with high-dose 131I-MIBG in patients with
PGLs with metastases may often result in sustained re-
mission or stable disease [9]. Similarly, treatment with
radiolabeled somatostatin receptor ligands may benefit
patients with high uptake observed on octreotide scintig-
raphy images [10].Conclusion
We present two cases of functional pancreatic PGLs.
Pancreatic PGLs have functional and malignant potential
requiring careful preoperative preparation, and close
postoperative follow-up should be considered for opti-
mal patient outcomes.Consent
Written informed consent was obtained from the pa-
tients or patient`s family members for publication of this
case. A copy of the written consents is available for re-
view by the Editor-in-Chief of this journal.
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